Price of Entrectinib after medical insurance reimbursement

Entrectinib is a multi-target oral tyrosine kinase inhibitor that mainly acts on patients with NTRK fusion protein, ROS1 and ALK-positive advanced solid tumors and non-small cell lung cancer (NSCLC). With its launch in China, entrectinib has been included in the scope of medical insurance reimbursement, allowing patients to receive greater financial support. The common specifications of the original drug in China are 100 mg with 30 pills and 200 mg with 90 pills, and the price per box is about more than 20,000 yuan. Through medical insurance reimbursement, patients' out-of-pocket costs are significantly reduced, making long-term targeted therapy more feasible.

After reimbursement by medical insurance, the actual out-of-pocket proportion of entrectinib varies depending on regional policies and patients' personal medical insurance conditions. However, overall, through medical insurance payment, the patient's monthly cost will be significantly reduced, which is of great significance for patients with advanced cancer. Since targeted therapies usually require continuous use for several months to a year or even longer, medical insurance reimbursement not only eases the financial burden, but also enables patients to use drugs continuously and standardizedly, improving efficacy and quality of life.

Improved economic accessibility of entrectinib also promotes the clinical use of this drug at an earlier stage. Taking NTRK fusion-positive advanced solid tumors as an example, early targeted therapy can significantly delay disease progression and control brain metastasis, which was difficult to achieve in patients who mainly relied on chemotherapy or first-line drugs in the past. In addition, medical insurance coverage means that more medical institutions can incorporate the drug into standardized treatment plans, allowing patients to receive standardized and scientific targeted treatment.

Overall, the inclusion of entrectinib in medical insurance reimbursement has reduced the financial burden on patients, improved drug accessibility, and provided a sustainable targeted treatment option for clinical practice, which has positive significance for improving the survival and quality of life of patients with advanced tumors.

Reference materials:https://www.roche.com/products/rozlytrek